Provided by Tiger Trade Technology Pte. Ltd.

Babson Capital Corporate Investors

20.72
+0.11000.53%
Post-market: 20.720.00000.00%16:10 EST
Volume:6.99K
Turnover:145.38K
Market Cap:424.73M
PE:13.27
High:20.98
Open:20.73
Low:20.57
Close:20.61
52wk High:23.79
52wk Low:18.00
Shares:20.50M
Float Shares:- -
Volume Ratio:0.44
T/O Rate:- -
Dividend:1.60
Dividend Rate:7.72%
EPS(TTM):1.56
EPS(LYR):1.74
ROE:9.13%
ROA:5.63%
PB:1.21
PE(LYR):11.88

Loading ...

Barings Corporate Investors Q4 net unrealized appreciation at USD 986,805.0 million after Q3 net unrealized depreciation of USD 419,454.0 million

Reuters
·
2 hours ago

Barings Corporate Investors Q4 Dividend USD 0.4

THOMSON REUTERS
·
3 hours ago

Press Release: Barings Corporate Investors Reports Preliminary Fourth Quarter 2025 Results

Dow Jones
·
3 hours ago

Barings Corporate Investors announces $0.40 per share quarterly dividend

Reuters
·
Dec 12, 2025

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

GlobeNewswire
·
Dec 04, 2025

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

GlobeNewswire
·
Dec 03, 2025

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

GlobeNewswire
·
Nov 28, 2025

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

GlobeNewswire
·
Nov 25, 2025

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

GlobeNewswire
·
Nov 14, 2025

Barings Corporate Investors reports Q3 net investment income of $7.1 million

Reuters
·
Nov 14, 2025

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

GlobeNewswire
·
Nov 05, 2025

India Inflation Cools Further in September

MT Newswires Live
·
Oct 14, 2025

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

GlobeNewswire
·
Oct 14, 2025

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

GlobeNewswire
·
Sep 24, 2025

How a new three-minute memory test can help spot Alzheimer's disease

Switzer
·
Sep 18, 2025

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

GlobeNewswire
·
Sep 03, 2025

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

GlobeNewswire
·
Sep 03, 2025